MAZICLAV-625 is a potent combination antibiotic tablet containing Amoxycillin 500 mg and Potassium Clavulanate 125 mg, specifically formulated to combat resistant bacterial infections effectively. Its dual-action mechanism targets a broad spectrum of gram-positive and gram-negative bacteria, making it ideal for treating respiratory, urinary tract, skin, and soft tissue infections. The inclusion of Potassium Clavulanate inhibits beta-lactamase enzymes produced by resistant bacteria, restoring the efficacy of Amoxycillin against plasmid-mediated resistance. MAZICLAV-625 boasts enhanced bioavailability and patient compliance due to its advanced formulation ensuring rapid bacterial clearance and facilitating quick clinical recovery. Supported by rigorous clinical studies and expert validation, it stands as a top-tier bactericidal solution designed for healthcare providers aiming to overcome the challenges posed by resistant pathogens. MAZICLAV-625 ensures consistent performance with minimal side effects, setting a new benchmark in antibiotic therapy for resistant infections.
Key Features
| Features | Description |
|---|---|
| Active Ingredients | Amoxycillin 500 mg + Potassium Clavulanate 125 mg |
| Mechanism of Action | Amoxycillin kills bacteria, Potassium Clavulanate inhibits beta-lactamase enzymes |
| Spectrum of Activity | Broad-spectrum against gram-positive and gram-negative bacteria |
| Indications | Respiratory, urinary tract, skin, and soft tissue infections |
| Formulation Benefits | Enhanced bioavailability and patient compliance |
| Resistance Management | Effective against plasmid-mediated beta-lactamase producing resistant bacteria |
| Clinical Validation | Supported by clinical studies and expert endorsement |
| Safety Profile | Proven minimal side effects with consistent therapeutic outcomes |
| Dosage Form | Oral tablets |
| Therapeutic Class | Broad-spectrum bactericidal antibiotic |
| Attributes | Description |
|---|---|
| Dosage Strength | 625 mg per tablet (500 mg Amoxycillin + 125 mg Potassium Clavulanate) |
| Dosage Form | Tablet |
| Route of Administration | Oral |
| Physicochemical Properties | White to off-white, round, biconvex tablet |
| Packaging | Blister packs or bottles, customizable based on order |
| Shelf Life | Typically 2 years from manufacturing |
| Storage Conditions | Store in a cool, dry place away from direct sunlight |
| Pharmacokinetics | Enhanced bioavailability due to clavulanate component |
| Regulatory Compliance | Manufactured following GMP guidelines |
| Manufacturer | Available upon inquiry (specific manufacturer details) |
| Target Market | Healthcare providers and pharmaceutical distributors |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
Maziclav-625 contains Potassium Clavulanate, which inhibits beta-lactamase enzymes that many resistant bacteria produce, thereby protecting Amoxycillin from degradation and restoring its bactericidal effectiveness.
Maziclav-625 is specifically effective against infections of the respiratory tract, urinary tract, skin, and soft tissues caused by both gram-positive and gram-negative bacteria including beta-lactamase producing strains.
Yes, the formulation of Maziclav-625 is designed for enhanced bioavailability and ease of administration, which promotes better patient compliance and suitability for outpatient treatment regimens.
The advanced formulation of Maziclav-625 ensures improved absorption and bioavailability, enabling rapid bacterial clearance and faster clinical recovery compared to older formulations.
Maziclav-625 is manufactured in compliance with GMP guidelines ensuring high-quality, safe, and consistently effective antibiotic tablets.
Revolutionize the battle against resistant bacteria with MAZICLAV-625. Our groundbreaking formula dismantles the shield of resistance, swiftly eliminating bacterial threats. Backed by cutting-edge technology and relentless research, MAZICLAV-625 stands as the pinnacle of bactericidal innovation. Elevate your approach to combating infections by choosing MAZICLAV-625 – the trusted ally in breaking the barriers of resistance.
MAZICLAV-625
Amoxycillin 500 mg + Potassium Clavulanate 125 mg Tablets
Amoxycillin
Broad spectrum of bactericidal activity against many gram-positive and gram-negative micro organism
Potassium Clavulanate
Activity against the clinically important plasmid-mediated
B-lactamases frequently responsible for transferred drug resistance.
MAZICLAV-625 combines amoxicillin and clavulanic acid to deliver broad-spectrum action against resistant pathogens. Ideal for respiratory, urinary, skin, and soft tissue infections, it ensures rapid bacterial clearance and clinical recovery. Its advanced formulation enhances bioavailability and patient compliance. Backed by clinical studies and expert endorsement, MAZICLAV-625 is your frontline defense in antibiotic therapy. Trust in its proven efficacy, minimal side effects, and consistent performance to redefine treatment standards in resistant bacterial infections.
Inclusive of all taxes
You Save: 0
Jaipur , India
Brand Owner, Distributor, Wholesaler, Women Entrepreneur
